0
     

Report Added
Report already added
Cerebral Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Cerebral Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 2, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cerebral Palsy - Overview
Cerebral Palsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cerebral Palsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cerebral Palsy - Companies Involved in Therapeutics Development
Baylx Inc
BrainRepair UG
Cell Tech Pharmed Co
CytoDel Inc
FamiCord Group
Help Therapeutics
Hope Biosciences LLC
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
Kashiv BioSciences LLC
Kidswell Bio Corp
Meridigen Biotech Co Ltd
MGC Pharmaceuticals Ltd
Revance Therapeutics Inc
Rohto Pharmaceutical Co Ltd
Cerebral Palsy - Drug Profiles
ANGES-001 - Drug Profile
Product Description
Mechanism Of Action
BXU-007 - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Neurology - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Neurology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
CepaCann - Drug Profile
Product Description
Mechanism Of Action
Cyto-012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
hNPC-01 - Drug Profile
Product Description
Mechanism Of Action
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Asherman Syndrome, Parkinson's Disease, Bronchial Fistula, Spastic Cerebral palsy, Primary Ovarian Insufficiency, Graft versus Host Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Uveitis, Hashimoto Thyroiditis, Systemic Lupus Erythematosus and Spinal Cord Injury - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Cerebral Palsy - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Cerebral Palsy and Pervasive Developmental Disorder - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
trihexyphenidyl hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
UDI-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
UMC-11910 - Drug Profile
Product Description
Mechanism Of Action
Vartocell - Drug Profile
Product Description
Mechanism Of Action
Cerebral Palsy - Dormant Projects
Cerebral Palsy - Product Development Milestones
Featured News & Press Releases
May 01, 2020: Revance and Mylan biosimilar to Botox program decision to extend beyond April 30, 2020
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Cerebral Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cerebral Palsy - Pipeline by Baylx Inc, 2022
Cerebral Palsy - Pipeline by BrainRepair UG, 2022
Cerebral Palsy - Pipeline by Cell Tech Pharmed Co, 2022
Cerebral Palsy - Pipeline by CytoDel Inc, 2022
Cerebral Palsy - Pipeline by FamiCord Group, 2022
Cerebral Palsy - Pipeline by Help Therapeutics, 2022
Cerebral Palsy - Pipeline by Hope Biosciences LLC, 2022
Cerebral Palsy - Pipeline by Hopstem Biotechnology LLC, 2022
Cerebral Palsy - Pipeline by iCELL Biotechnology Co Ltd, 2022
Cerebral Palsy - Pipeline by Kashiv BioSciences LLC, 2022
Cerebral Palsy - Pipeline by Kidswell Bio Corp, 2022
Cerebral Palsy - Pipeline by Meridigen Biotech Co Ltd, 2022
Cerebral Palsy - Pipeline by MGC Pharmaceuticals Ltd, 2022
Cerebral Palsy - Pipeline by Revance Therapeutics Inc, 2022
Cerebral Palsy - Pipeline by Rohto Pharmaceutical Co Ltd, 2022
Cerebral Palsy - Dormant Projects, 2022

List of Figures
Number of Products under Development for Cerebral Palsy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Cerebral Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW